Home › Companies › Mirum Pharmaceuticals, Inc. › 2024-2025

Mirum Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Mirum Pharmaceuticals, Inc.’s Form 8-K, filed 2025-05-30 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
247Asset managers
1,323Fund votes
2025-05-29Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Mirum Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Mirum Pharmaceuticals, Inc.

These tallies are Mirum Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-30 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Mirum Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2025-05-29
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Laura Brege	17,968,766	--	--	18,167,097	7,017,835	Plurality election
Elect Director: Michael Grey	30,777,470	--	--	5,358,393	7,017,835	Majority: yes
Elect Director: Christopher Peetz	35,980,278	--	--	155,585	7,017,835	Majority: yes
Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's in	43,115,134	19,188	19,376	--	--	Majority: yes
Proposal 3. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement for the Annual Meeting.	34,671,826	1,455,143	8,894	--	7,017,835	Majority: yes

Source: Mirum Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2025-05-30 — read the filing on EDGAR.

How asset managers voted at the Mirum Pharmaceuticals, Inc. 2024-2025 meeting

Each item below shows how the 247 asset managers that disclosed a Mirum Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Mirum Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

COMPENSATIONMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 34,671,826AGAINST: 1,455,143

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement for the Annual”): 34,671,826 for, 1,455,143 against, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,451,223 outstanding shares: 70% for, 3% against (73% of the company cast a for/against vote).

The 245 asset managers below cast 97% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 97%

FOR: 96.7%AGAINST: 3.3%ABSTAIN: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Vote
Janus Henderson	4,677,659	For
BVF INC/IL	2,761,333	For
Vanguard	2,596,361	For
MUTUAL FUND SERIES TRUST	2,516,344	For
T. Rowe Price	2,331,972	For
BlackRock	1,991,793	For
JANUS INVESTMENT FUND	1,880,346	For
State Street	1,822,222	For
Novo Holdings A/S	1,500,000	For
Clearbridge Investments, LLC	968,546	For
Rock Springs Capital Management LP	951,765	For
Loomis Sayles	884,583	For
Fidelity	830,372	For
Legg Mason	794,740	For
GEODE CAPITAL MANAGEMENT, LLC	732,335	For
Citadel	727,381	For
PICTET ASSET MANAGEMENT SA	704,954	For
Nuveen	676,249	For
Federated Hermes	663,060	For
Charles Schwab	655,386	For
TIAA	628,349	For
BOONE CAPITAL MANAGEMENT LLC	603,318	For
FRANKLIN ADVISERS INC	592,514	For
LORD, ABBETT & CO. LLC	588,552	For
Invesco	587,787	For

Showing the 25 largest of 245 asset managers. See all 245 in the interactive database.

2. To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Christopher Peetz

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 35,980,278WITHHELD: 155,585

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christopher Peetz”): 35,980,278 for, 155,585 withheld, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,451,223 outstanding shares: 73% for, 0.4% withheld (73% of the company cast a for/withheld vote).

The 75 asset managers below cast 100% of the shares they voted on this item FOR (15,326,402 for, 0 against).

FOR 98%

FOR: 15,326,402 (98.3%)ABSTAIN: 263,228 (1.7%)

Largest asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meet” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Abstain	Vote
MUTUAL FUND SERIES TRUST	2,516,344	0	For
Vanguard	2,491,637	0	For
JANUS INVESTMENT FUND	1,880,346	0	For
BlackRock	1,084,414	0	For
T. Rowe Price	982,103	0	For
Legg Mason	794,740	0	For
Fidelity	776,976	0	For
TIAA	628,349	0	For
State Street	521,162	0	For
Lord Abbett	379,282	0	For
Loomis Sayles	329,204	0	For
Charles Schwab	327,690	0	For
Federated Hermes	327,010	0	For
Invesco	284,600	0	For
Erste Asset Management GmbH	0	260,000	Abstain
Waddell & Reed	247,779	0	For
FRANKLIN STRATEGIC SERIES	215,190	0	For
Columbia Threadneedle	157,331	0	For
Equitable	149,393	0	For
First Trust	128,774	0	For
Brighthouse	111,881	3,228	For
Russell Investments	94,313	0	For
Calamos	85,593	0	For
BNY Mellon	82,426	0	For
QUANTITATIVE MASTER SERIES LLC	67,687	0	For

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

3. To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Laura Brege

DIRECTOR ELECTIONSCompany result: Plurality election

Combines 4 wordings of this item as funds reported it.

49.7% Plurality election · of votes cast

FOR 49.7%WITHHELD 50.3%

FOR: 17,968,766WITHHELD: 18,167,097

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Laura Brege”): 17,968,766 for, 18,167,097 withheld, per its Form 8-K filed 2025-05-30 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here. Of all 49,451,223 outstanding shares: 36% for, 37% withheld (73% of the company cast a for/withheld vote).

The 75 asset managers below cast 100% of the shares they voted on this item FOR (9,407,003 for, 0 against).

FOR 60%ABSTAIN 40%

FOR: 9,407,003 (60.3%)ABSTAIN: 6,182,627 (39.7%)

Largest asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meet” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Abstain	Vote
MUTUAL FUND SERIES TRUST	2,516,344	0	For
Vanguard	2,459,937	31,700	For
JANUS INVESTMENT FUND	0	1,880,346	Abstain
BlackRock	11,375	1,073,039	Abstain
T. Rowe Price	982,103	0	For
Legg Mason	792,193	2,547	For
Fidelity	738,035	38,941	For
TIAA	628,349	0	For
State Street	1,274	519,888	Abstain
Lord Abbett	0	379,282	Abstain
Loomis Sayles	0	329,204	Abstain
Charles Schwab	327,690	0	For
Federated Hermes	327,010	0	For
Invesco	0	284,600	Abstain
Erste Asset Management GmbH	260,000	0	For
Waddell & Reed	0	247,779	Abstain
FRANKLIN STRATEGIC SERIES	0	215,190	Abstain
Columbia Threadneedle	0	157,331	Abstain
Equitable	0	149,393	Abstain
First Trust	0	128,774	Abstain
Brighthouse	33,180	81,929	Abstain
Russell Investments	0	94,313	Abstain
Calamos	85,593	0	For
BNY Mellon	82,426	0	For
QUANTITATIVE MASTER SERIES LLC	0	67,687	Abstain

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

4. To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Michael Grey

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 30,777,470WITHHELD: 5,358,393

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Michael Grey”): 30,777,470 for, 5,358,393 withheld, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,451,223 outstanding shares: 62% for, 11% withheld (73% of the company cast a for/withheld vote).

The 75 asset managers below cast 100% of the shares they voted on this item FOR (13,359,903 for, 0 against).

FOR 86%ABSTAIN 14%

FOR: 13,359,903 (85.7%)ABSTAIN: 2,229,727 (14.3%)

Largest asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meet” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Abstain	Vote
MUTUAL FUND SERIES TRUST	2,516,344	0	For
Vanguard	2,491,637	0	For
JANUS INVESTMENT FUND	1,880,346	0	For
BlackRock	0	1,084,414	Abstain
T. Rowe Price	982,103	0	For
Legg Mason	794,740	0	For
Fidelity	760,735	16,241	For
TIAA	628,349	0	For
State Street	1,862	519,300	Abstain
Lord Abbett	379,282	0	For
Loomis Sayles	329,204	0	For
Charles Schwab	327,690	0	For
Federated Hermes	327,010	0	For
Invesco	284,600	0	For
Erste Asset Management GmbH	260,000	0	For
Waddell & Reed	0	247,779	Abstain
FRANKLIN STRATEGIC SERIES	215,190	0	For
Columbia Threadneedle	157,331	0	For
Equitable	36,883	112,510	Abstain
First Trust	128,774	0	For
Brighthouse	111,881	3,228	For
Russell Investments	94,313	0	For
Calamos	85,593	0	For
BNY Mellon	82,426	0	For
QUANTITATIVE MASTER SERIES LLC	0	67,687	Abstain

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

5. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 43,115,134AGAINST: 19,188

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 43,115,134 for, 19,188 against, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,451,223 outstanding shares: 87% for, 0.1% against (87% of the company cast a for/against vote).

The 74 asset managers below cast 100% of the shares they voted on this item FOR (15,585,233 for, 0 against).

FOR 99.9%

FOR: 15,585,233 (100.0%)ABSTAIN: 3,228 (0.0%)

Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independe” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Abstain	Vote
MUTUAL FUND SERIES TRUST	2,516,344	0	For
Vanguard	2,491,637	0	For
JANUS INVESTMENT FUND	1,880,346	0	For
BlackRock	1,084,414	0	For
T. Rowe Price	982,103	0	For
Legg Mason	794,740	0	For
Fidelity	776,976	0	For
TIAA	628,349	0	For
State Street	521,162	0	For
Lord Abbett	379,282	0	For
Loomis Sayles	329,204	0	For
Charles Schwab	327,690	0	For
Federated Hermes	327,010	0	For
Invesco	284,600	0	For
Erste Asset Management GmbH	260,000	0	For
Waddell & Reed	247,779	0	For
FRANKLIN STRATEGIC SERIES	215,190	0	For
Columbia Threadneedle	157,331	0	For
Equitable	149,393	0	For
First Trust	128,774	0	For
Brighthouse	111,881	3,228	For
Russell Investments	94,313	0	For
Calamos	85,593	0	For
BNY Mellon	82,426	0	For
QUANTITATIVE MASTER SERIES LLC	67,687	0	For

Showing the 25 largest of 74 asset managers. See all 74 in the interactive database.

6. Ratify Appointment of Independent Auditors

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 43,115,134AGAINST: 19,188

The 2 asset managers below cast 100% of the shares they voted on this item FOR (21,025 for, 0 against).

FOR 100%

FOR: 21,025 (100.0%)

Largest asset managers voting on “Ratify Appointment of Independent Auditors” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
RBB Fund Trust	19,856	0	0	0	For
Virtus	1,169	0	0	0	For

Largest Mirum Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked by the number of Mirum Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 49,451,223 shares outstanding at the time of that meeting.

Top Mirum Pharmaceuticals, Inc. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Janus Henderson	9.46%
2	BVF INC/IL	5.58%
3	Vanguard	5.25%
4	MUTUAL FUND SERIES TRUST	5.09%
5	T. Rowe Price	4.72%
6	BlackRock	4.03%
7	JANUS INVESTMENT FUND	3.80%
8	State Street	3.68%
9	Novo Holdings A/S	3.03%
10	Clearbridge Investments, LLC	1.96%

Reported Mirum Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Mirum Pharmaceuticals, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
JANUS HENDERSON GROUP PLC	12.27%	13G
James N. Topper	8.14%	13D
Patrick Heron	7.68%	DEF14A
Frazier Life Sciences IX, L.P.	7.21%	13D
BlackRock	6.75%	13F
Biotechnology Value Fund, L.P.	6.22%	DEF14A
Vanguard Group	5.14%	13F
Eventide Asset Management, LLC	4.23%	13G
Christopher Peetz	3.47%	DEF14A
BVF PARTNERS L P/IL	3.02%	13G

Percentages above are of 49,451,223 shares outstanding, as reported by Mirum Pharmaceuticals, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Mirum Pharmaceuticals, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Mirum Pharmaceuticals, Inc.'s shareholder meeting held 2025-05-29, in the 2024-2025 proxy season, 247 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,323 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Mirum Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-30.

Mirum Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.